Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) [clinicaltrials:NCT02513472]
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) [clinicaltrials:NCT02513472]
Bio2RDF identifier
NCT02513472
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT02513472
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
This is an open-label, ...... ns in the metastatic setting.
brief title [clinicaltrials_vocabulary:brief-title]
Study to Evaluate the Efficacy ...... Negative Breast Cancer (mTNBC)
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2017-04-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
detailed description [clinicaltrials_vocabulary:detailed-description]
The Phase 1b part will ...... be enrolled in Phase 2 part.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2015-07-29T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
Eribulin Mesylate
Metastatic Triple-Negative Breast Cancer
Pembrolizumab
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2015-07-30T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
nct id [clinicaltrials_vocabulary:nct-id]
NCT02513472
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
An Open-Label, Single-Arm Mult ...... Negative Breast Cancer (mTNBC)
org study id [clinicaltrials_vocabulary:org-study-id]
E7389-M001-218
overall contact [clinicaltrials_vocabulary:overall-contact]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2017-02-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
KEYNOTE-150
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2015-08-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2015-07-01T00:00:00Z
identifier
clinicaltrials:NCT02513472
title
Study to Evaluate the Efficacy ...... Negative Breast Cancer (mTNBC)
@en